Brief: Avita Medical Expects FDA Approval For Soft Tissue Repair Indication In June 2023

AVITA Medical

24/02/2023 06:15

Feb 24 (Reuters) - AVITA Medical Inc  RCEL.O :
    * EXPECT FDA APPROVAL FOR SOFT TISSUE REPAIR INDICATION IN
JUNE
2023 FOLLOWED BY COMMERCIAL LAUNCH ON JULY 1, 2023
    * EXPECT FDA APPROVAL FOR VITILIGO INDICATION IN JUNE 2023
    * COMMERCIAL REVENUE, WHICH EXCLUDES BARDA REVENUE, FOR Q1
2023 IS
EXPECTED TO BE IN RANGE OF $10 TO $11 MILLION
    * COMMERCIAL REVENUE, WHICH EXCLUDES BARDA REVENUE, FOR FULL
YEAR
2023 IS EXPECTED TO BE IN RANGE OF $49 TO $51 MILLION

Source text for Eikon:  ID:nASX6jmwDT 
Further company coverage:  RCEL.O 
 ((reuters.briefs@thomsonreuters.com;))